BSG endoscopy section symposium and free papers: Dealing with endoscopic disasters - "How I do it"

OC-011 ENDOSCOPIC THERAPY IN BARRETT'S OESOPHAGUS (BE) WITH HGD (HIGH GRADE DYSPLASIA) AND EARLY MALIGNANCY; A PROSPECTIVE, SINGLE CENTRE EXPERIENCE

doi:10.1136/gutjnl-2012-302514a.11

¹H C McEwan,* ²A J Morris, ³P Glen, ⁴J E Abela, ⁵J J Going, ^{1,6}G Fullarton.
¹Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK; ²Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK; ³Department of Surgery, Southern General Hospital, Glasgow, UK; ⁴Department of Surgery, Royal Alexandra Hospital, Glasgow, UK; ⁵Department of Pathology, Glasgow Royal Infirmary, Glasgow, UK; ⁶Department of Surgery, AUGIS, Glasgow, UK

Introduction There is increasing evidence that endoscopic therapy in BE with a combination of endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) is an effective treatment of intra-mucosal cancer (IMC) and HGD. The widespread application of this therapy is yet to be assessed in the UK outside the trial setting. We present here the results of a single centre study from a large tertiary referral teaching hospital. We aim to assess the efficacy and safety of endoscopic therapy with EMR and RFA in the treatment of HGD and IMC.

Methods 102 consenting patients with a mean age of 69 (range 42–89) with HGD or IMC were enrolled between July 2008 and September 2011. All pathology was reviewed by a pathologist with a particular interest in Barrett's. The treatment protocol involved EMR of all nodular areas with subsequent RFA of all remaining Barretts epithelium. The RFA technique involved a combination of circumferential RFA (HALO 360) followed by subsequent focal ablation (HALO 90) of residual areas of Barrett's tongues or islands. The UK protocol involved a maximum of two HALO 360's and 3 HALO 90's.

Results 102 patients have been recruited (30 with IMC and 72 with HGD). Fifty patients have completed the treatment protocol (median of 1 HALO 360 and 1 HALO 90) and of these, 52% had initial EMR. Median follow-up in this group was 9 months (range 3–41). Thirteen of these 50 patients had IMC (26%) with 37 patients demonstrating flat HGD only. Of the 102 patients recruited, nine patients (8.7%) have progressed to invasive malignancy after a median of 12 months. As a result, there were 59 patients who exited the protocol following an intention to treat. To date eradication of dysplasia was achieved in 49/59 patients (83%) and eradication of metaplasia in 40/59 patients (68%). Three patients died from unrelated causes, two from cardiorespiratory comorbidities and one from concurrent lymphoma. Eight patients (8%) developed mild strictures. One patient required readmission for retrosternal pain requiring analgesia. There were no serious complications or peri-procedural mortality.

Conclusion This study demonstrates the efficacy of endotherapy with EMR and RFA in the treatment of IMC and HGD. Although further follow-up is required, these results suggest that such therapy should be offered to all patients as an alternative to surgery.

Competing interests None declared.

OC-012 A STRUCTURED EVALUATION OF PATIENT SAFETY INCIDENTS AND NEVER EVENTS IN ENDOSCOPY

doi:10.1136/gutjnl-2012-302514a.12

^{1,2}M K Matharoo,* ¹A Haycock, ³N Sevdalis, ¹S Thomas-Gibson. ¹Endoscopy, St Mark's Hospital, Harrow, UK; ²Centre for Patient Safety and Service Quality (CPSSQ), Imperial College, London, UK; ³CPSSQ, Imperial College, London, UK

Introduction Medical error is common and causes significant morbidity and mortality.¹ A significant proportion of adverse events

are deemed to be preventable and often arise from multiple systems failures as per Reason's "Swiss Cheese" model. The DOH's "never events" (NE) are defined as serious but preventable patient safety incidents (PSI). These include overdose of midazolam during conscious sedation & failure to monitor/respond to oxygen saturations, which are anecdotally common. NHS Trusts are incentivised to prevent NEs as serious financial penalties are incurred. To further improve quality and safety in Endoscopy, a structured analysis of current safety pitfalls is relevant, particularly in the context of the NHS Bowel Cancer Screening programme, where increasing numbers of asymptomatic individuals will undergo an endoscopic procedure.

Methods All types of GI endoscopic procedures were prospectively observed in a single tertiary endoscopy unit by a Gastroenterologist trained in patient safety and behavioural observation. A representative sample of Endoscopists by specialty (physician, surgeon & nurse) & grade (trainee, consultant & BCS Endoscopist) were recruited. The procedures were observed from within the endoscopy room or via AV live link with a tri-split screen (team, luminal and scope guide views). The medical record, nursing notes & endoscopy reports were also reviewed. All PSIs (defined as near misses, adverse events or NEs) were qualitatively recorded and subsequently categorised by expert consensus for type (clinical, process or human error) & severity (1=Mild 2=Moderate 3=Severe).

Results 90 procedures (22 lists, 16 Endoscopists) were analysed. A total of 41 PSIs were identified (PSI rate = 45%). 51% (n=21) of these were categorised as "severe" & 24% (n=10) had the potential to be full NEs. The Abstract OC-012 table 1 illustrates some examples of severe PSIs:

Abstract OC-012 table 1 Examples of patient safety incidents

Patient safety incident (PSI)	Never event	Severity	Frequency
Patient mis-identification	Y	3	1
Incorrect procedure (colonoscopy instead of FS)	Y	3	1
Sedated patient in corridor unmonitored	Y	3	2
Sedation with no O ₂ saturation monitor	Y	3	2
PPH (re-scope under GA & overnight admission)	N	3	1
Polypectomy without IV access	N	3	1

FE, flexible sigmoidoscopy; PPH, post-polypectomy haemorrhage.

Conclusion This study is the first attempt to identify and categorise relevant Endoscopy PSIs in a structured fashion. Findings indicate that PSIs may be more common than previously thought. While PSIs in this study did not incur serious consequences for patients, they represent a latent risk & should be addressed. The focus for adverse events should shift from that of "reporting" to "understanding" the multifaceted reasons why a PSI occurred. Near misses represent a golden opportunity to intervene proactively. Further studies will examine the root cause for these errors & whether PSIs & never events can be reduced by implementing and validating an Endoscopy Safety Checklist.

Competing interests M Matharoo grant/research support from: The NHS BCS research programme, conflict with: the freemasons grand charity, A Haycock: None declared, N Sevdalis: None declared, S Thomas-Gibson: None declared.

REFERENCE

1. Vincent, et al. Adverse events in British Hospitals: preliminary retrospective record review. *BMJ* 2001;**322**.

OC-013 HOSPITAL ATTENDANCES AFTER OUTPATIENT COLONOSCOPY: THE HIDDEN HEALTHCARE BURDEN?

doi:10.1136/gutjnl-2012-302514a.13

S Stevens,* L Sergot, J Mawdsley, C E Collins, I Beveridge, K Sundaram, K J Monahan. West Middlesex University Hospital, NHS, London, UK

Introduction With the introduction of national bowel cancer screening and increased surveillance, colonoscopy is being